Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim plus D-VCd in Untreated AL Amyloidosis
2024-518658-18-00Phase 2Authorised
- Sponsor
- Medical University of Warsaw
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim, daratumumab, bortezomib, cyclophosphamide and dexamethasone in light-chain amyloidosis, sponsored by Medical University of Warsaw. Primary endpoints: Complete hematologic response rate (CHRR) and Serious adverse events rate. Planned start Dec 2024; status: authorised.
02
Drugs
sargramostimdaratumumabbortezomibcyclophosphamidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2024-518658-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518658-18-00.